Corticotropin-releasing hormone induces vascular endothelial growth factor release from human mast cells via the cAMP/protein kinase A/p38 mitogen-activated protein kinase pathway

Molecular Pharmacology

Volumn 69, Issue 3, 2006, Pages 998-1006

  Cao, Jing ^a   Cetrulo, Curtis L ^b   Theoharides, Theoharis C ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 8 BROMO CYCLIC AMP; 9 (TETRAHYDRO 2 FURYL)ADENINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CORTICOTROPIN RELEASING FACTOR; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; STRESS ACTIVATED PROTEIN KINASE; VASCULOTROPIN;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; MAST CELL; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN SECRETION;

ADENINE; ADENYLATE CYCLASE; CALCIUM; CELLS, CULTURED; CORTICOTROPIN-RELEASING HORMONE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAST CELLS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33644839259     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.019539     Document Type: Article

References (58)

1. Amano H, Ando K, Minamida S, Hayashi I, Ogino M, Yamashina S, Yoshimura H, and Majima M (2001) Adenylate cyclase/protein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in vivo. Jpn J Pharmacol 87:181-188.
2. Anand KJS and Hickey PR (1992) Halothane-morphine compared with high-dose sufentanil for anesthesia and postoperative analgesia in neonatal cardiac surgery. N Engl J Med 326:1-9.
3. Aoki Y, Iwasaki Y, Katahira M, Oiso Y, and Saito H (1997) Regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. I: effects of the common secretagogues. Endocrinology 138:1923-1929.
4. Bhushan M, McLaughlin B, Weiss JB, and Griffiths CE (1999) Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 141:1054-1060.
5. Bienenstock J (2002) Stress and asthma: the plot thickens. Am J Respir Crit Care Med 165:1034-1035.
6. Boesiger J, Tsai M, Maurer M, Yamaguchi M, Brown LF, Claffey KP, Dvorak HF, and Galli SJ (1998) Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of Fcε receptor I expression. J Exp Med 188:1135-1145.
7. Cao J, Papadopoulou N, Kempuraj D, Boucher WS, Sugimoto K, Cetrulo CL, and Theoharides TC (2005) Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor (VEGF). J Immunol 174:7665-7675.
8. Chen AM, Perrin MH, Digruccio MR, Vaughan JM, Brar BK, Arias CM, Lewis KA, Rivier JE, Sawchenko PE, and Vale WW (2005) A soluble mouse brain splice variant of type 2α corticotropin-releasing factor (CRF) receptor binds ligands and modulates their activity. Proc Natl Acad Sci USA 102:2620-2625.
9. Cheng T, Cao W, Wen R, Steinberg RH, and LaVail MM (1998) Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Investig Ophthalmol Vis Sci 39:581-591.
10. Dermitzaki E, Tsatsanis C, Gravanis A, and Margioris AN (2002) Corticotropin-releasing hormone induces fas ligand production and apoptosis in PC12 cells via activation of P38 mitogen-activated protein kinase. J Biol Chem 277:12280-12287.
11. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B, and Dvorak HF (1994) Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180:1141-1146.
12. Dibbens JA, Miller DL, Damert A, Risau W, Vadas MA, and Goodall GJ (1999) Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements. Mol Biol Cell 10:907-919.
13. Escribano L, Akin C, Castells M, Orfao A, and Metcalfe DD (2002) Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 81:677-690.
14. Eubank TD, Galloway M, Montague CM, Waldman WJ, and Marsh CB (2003) M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J Immunol 171:2637-2643.
15. Fazal N, Slominski A, Choudhry MA, Wei ET, and Sayeed MM (1998) Effect of CRF and related peptides on calcium signaling in human and rodent melanoma cells. FEBS Lett 435:187-190.
16. Grammatopoulos DK and Chrousos GP (2002) Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol Metab 13:436-444.
17. Graziani G, Tentori L, Portarena I, Barbarino M, Tringali G, Pozzoli G, and Navarra P (2002) CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of CAMP-PKA pathway. Endocrinology 143:807-813.
18. Hoper MM, Voelkel NF, Bates TO, Allard JD, Horan M, Shepherd D, and Tuder RM (1997) Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. Am J Respir Cell Mol Biol 17:748-756.
19. Horiuchi T and Weller PF (1997) Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Am J Respir Cell Mol Biol 17:70-77.
20. Johnson GL and Lapadat R (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK and P38 protein kinases. Science (Wash DC) 298:1911-1912.
21. Kakita A, Suzuki A, Ono Y, Miura Y, Itoh M, and Oiso Y (2004) Possible involvement of P38 MAP kinase in prostaglandin E1-induced ALP activity in osteoblast-like cells. Prostaglandins Leukot Essent Fatty Acids 70:469-474.
22. Karalis K, Louis JM, Bae D, Hilderbrand H, and Majzoub JA (1997) CRH and the immune system. J Neuroimmunol 72:131-136.
23. Katsarou-Katsari A, Filippou A, and Theoharides TC (1999) Effect of stress and other psychological factors on the pathophysiology and treatment of dermatoses. Int J Immunopathol Pharmacol 12:7-11.
24. Kempuraj D, Saito H, Kaneko A, Fukagawa K, Nakayama M, Toru H, Tomikawa M, Tachimoto H, Ebisawa M, Akasawa A, et al. (1999) Characterization of mast cell-committed progenitors present in human umbilical cord blood. Blood 93:3338-3346.
25. 2+] in human epidermoid A-431 cells. Eur J Pharmacol 329:237-244.
26. Kovalovsky D, Refojo D, Liberman AC, Hochbaum D, Pereda MP, Coso OA, Stalla GK, Holsboer F, and Arzt E (2002) Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A and MAPK pathways. Mol Endocrinol 16:1638-1651.
27. Kyriakis JM and Avruch J (2001) Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81:807-869.
28. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, et al. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature (Lond) 372:739-746.
29. Loureiro RM and D'Amore PA (2005) Transcriptional regulation of vascular endothelial growth factor in cancer. Cytokine Growth Factor Rev 16:77-89.
30. Lu HT, Yang DD, Wysk M, Gatti E, Mellman I, Davis RJ, and Flavell RA (1999) Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice. EMBO (Eur Mol Biol Organ) J 18:1845-1857.
31. Marie C, Roman-Roman S, and Rawadi G (1999) Involvement of mitogen-activated protein kinase pathways in interleukin-8 production by human monocytes and polymorphonuclear cells stimulated with lipopolysaccharide or mycoplasma fermentans membrane lipoproteins. Infect Immun 67:688-693.
32. McEvoy AN, Bresnihan B, FitzGerald O, and Murphy EP (2002) Corticotropin-releasing hormone signaling in synovial tissue vascular endothelium is mediated through the cAMP/CREB pathway. Ann NY Acad Sci 966:119-130.
33. Pages G, Berra E, Milanini J, Levy AP, and Pouyssegur J (2000) Stress-activated protein kinases (JNK and P38/HOG) are essential for vascular endothelial growth factor mRNA stability. J Biol Chem 275:26484-26491.
34. Park HJ, Kim HJ, Lee JH, Lee JY, Cho BK, Kang JS, Kang H, Yang Y, and Cho DH (2005) Corticotropin-releasing hormone (CRH) downregulates interleukin-18 expression in human HaCaT keratinocytes by activation of P38 mitogen-activated protein kinase (MAPK) pathway. J Investig Dermatol 124:751-755.
35. Park JH, Park JK, Bae KW, and Park HT (2000) Protein kinase A activity is required for depolarization-induced proline-rich tyrosine kinase 2 and mitogen-activated protein kinase activation in PC12 cells. Neurosci Lett 290:25-28.
36. Pisarchik A and Slominski A (2004) Molecular and functional characterization of novel CRFR1 isoforms from the skin. Eur J Biochem 271:2821-2830.
37. Salas MA, Brown OA, Perone MJ, Castro MG, and Goya RG (1997) Effect of the corticotropin releasing hormone precursor on interleukin-6 release by human mononuclear cells. Clin Immunol Immunopathol 85:35-39.
38. Schafer PH, Wadsworth SA, Wang L, and Siekierka JJ (1999) P38 alpha mitogen-activated protein kinase is activated by CD28-mediated signaling and is required for IL-4 production by human CD4+CD45RO+ T cells and Th2 effector cells. J Immunol 162:7110-7119.
39. Singh VK and Leu CSJ (1990) Enhancing effect of corticotropin-releasing neurohormone on the production of interleukin-1 and interleukin-2. Neurosci Lett 120:151-154.
40. Siraganian RP (2003) Mast cell signal transduction from the high-affinity IgE receptor. Curr Opin Immunol 15:639-646.
41. Tamaki M, Saito R, Ogawa O, Yoshimura N, and Ueda T (2004) Possible mechanisms inducing glomerulations in interstitial cystitis: relationship between endoscopic findings and expression of angiogenic growth factors. J Urol 172:945-948.
42. Tanabe K, Dohi S, Matsuno H, Hirade K, and Kozawa O (2003) Midazolam stimulates vascular endothelial growth factor release in aortic smooth muscle cells: role of the mitogen-activated protein kinase superfamily. Anesthesiology 98:1147-1154.
43. Theoharides TC and Cochrane DE (2004) Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 146:1-12.
44. Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, and Conti P (2004) Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci 25:563-568.
45. Theoharides TC, Kempuraj D, and Sant GR (2001) Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology 57:47-55.
46. Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E, and Chrousos G (1998) Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 139:403-413.
47. Tokuda H, Hatakeyama D, Akamatsu S, Tanabe K, Yoshida M, Shibata T, and Kozawa O (2003a) Involvement of MAP kinases in TGF-beta-stimulated vascular endothelial growth factor synthesis in osteoblasts. Arch Biochem Biophys 415:117-125.
48. Tokuda H, Hatakeyama D, Shibata T, Akamatsu S, Oiso Y, and Kozawa O (2003b) P38 MAP kinase regulates BMP-4-stimulated VEGF synthesis via P70 S6 kinase in osteoblasts. Am J Physiol 284:E1202-E1209.
49. Tokuda H, Kozawa O, and Uematsu T (2000) Basic fibroblast growth factor stimulates vascular endothelial growth factor release in osteoblasts: divergent regulation by P42/P44 mitogen-activated protein kinase and P38 mitogen-activated protein kinase. J Bone Miner Res 15:2371-2379.
50. Trompezinski S, Pernet I, Schmitt D, and Viac J (2001) UV radiation and prostaglandin E2 up-regulate vascular endothelial growth factor (VEGF) in cultured human fibroblasts. Inflamm Res 50:422-427.
51. Wang W, Ji P, and Dow KE (2003) Corticotropin-releasing hormone induces proliferation and TNF-alpha release in cultured rat microglia via MAP kinase signalling pathways. J Neurochem 84:189-195.
52. Wang X, Tokuda H, Hirade K, and Kozawa O (2002) Stress-activated protein kinase/c-Jun N-terminal kinase (JNK) plays a part in endothelin-1-induced vascular endothelial growth factor synthesis in osteoblasts. J Cell Biochem 87:417-423.
53. Wery-Zennaro S, Zugaza JL, Letourneur M, Bertoglio J, and Pierre J (2000) IL-4 regulation of IL-6 production involves Rac/Cdc42- and P38 MAPK-dependent pathways in keratinocytes. Oncogene 19:1596-1604.
54. Wiesner B, Roloff B, Fechner K, and Slominski A (2003) Intracellular calcium measurements of single human skin cells after stimulation with corticotropin-releasing factor and urocortin using confocal laser scanning microscopy. J Cell Sci 116:1261-1268.
55. Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, and Rudge JS (2003) Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102:161-168.
56. Xiong Y, Xie LY, and bou-Samra AB (1995) Signaling properties of mouse and human corticotropin-releasing factor (CRF) receptors: decreased coupling efficiency of human type II CRF receptor. Endocrinology 136:1828-1834.
57. Xu L, Pathak PS, and Fukumura D (2004) Hypoxia-induced activation of P38 mitogen-activated protein kinase and phosphatidylinositol 3′-kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells. Clin Cancer Res 10:701-707.
58. Zbytek B, Mysliwski A, Slominski A, Wortsman J, Wei ET, and Mysliwska J (2002) Corticotropin-releasing hormone affects cytokine production in human HaCaT keratinocytes. Life Sci 70:1013-1021.